This is important, as the use of bone SPECT/CT in the diagnosis of prostate cancer may decline due to the increased use of PSMA PET and SPECT ligands in the near future, which will allow for the detection of both bone and soft tissue metastases [33, 34]. This evidence concerns the gene FOLH1 and Familial prostate cancer.